iRadimed Sees Q2 Adj EPS $0.44-$0.48 vs $0.47 Est; Sees Sales $20.000M-$21.000M vs $21.134M Est

Benzinga Newsdesk www.benzinga.com Neutral 75.1%

Neg 0% Neu 75.1% Pos 0%

iRadimed (NASDAQ:IRMD) is looking for Q2 Adj EPS of $0.44-$0.48 vs $0.47 analyst estimate. sees sales of $20.000 million-$21.000 million vs $21.134 million analyst estimate.